Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection
Table 2
Population parameter estimates (μ, σ) estimated by simultaneously fitting our model (Eqs 13–20) to data of V, A1 and A2 from untreated macaques and responders (Methods).
Standard errors (SE) are shown in brackets.